Editas Medicine to Host Conference Call Discussing Second Quarter 2018 Corporate Update and Results CAMBRIDGE, Mass., July 30, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday,...

Editas Medicine to Host Conference Call Discussing Third Quarter 2017 Corporate Update and Results CAMBRIDGE, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday,...

Editas Medicine to Present Data on CRISPR/Cas9-mediated Gene Editing in Hematopoietic Stem/Progenitor Cells at ESGCT-ISSCR 2016 CAMBRIDGE, Mass., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that its scientists will present data on the use of...

Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines CAMBRIDGE, Mass., May 16, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced a three-year agreement with Cystic Fibrosis Foundation...